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S_ary Recent data have shown that the in vitro and in vivo cytotoxicity of bioreductive drugs could be
significantly increased when combined with chemotherapy drugs such as cisplatinum, depending on the timing
of administration. The aim of this study was to define the toxicity (animal lethaity) and the activity (growth
delay assay, excision assay) of a bioreductive drug, tirapazamine, alone and combined with chemotherapy
agents (5-FU, VP16, bleo, DTIC and c-DDP) on nude mice bearing xenografted human tumours: a rectal
carcinoma (HRT18) and a melanoma (NalI +). Animal lethality was markedly increased when tirapazamine at
the lethal dose 10% was combined with the other drugs. For the HRT18 tumour the combination of
tirapazamine and bleomycin significantly increased the delay of regrowth compared with bleomycin alone
(P=0.04) and was more cytotoxic than tirapazamine alone (P=0.04). For the Nall+ tumours the
combination of tirapazamine with VP16 significantly increased tumour doubling time compared with the
controls (P=0.001) or VP16 alone. The combination oftirapazamine and VP16 was more cytotoxic than VP16
alone (P=0.0001). When compared with c-DDP or tirapazamine alone, there was a significant decrease in
plating efficiency when tirapazamine and c-DDP were given at the same time (P=0.04), but not when
tirapazamine was given 3 h before c-DDP. In conclusion, tirapazamine was shown to be cytotoxic against
clonogenic human tumour cells. Its efficacy in vivo may depend on its combination with already active
chemotherapy drugs on the tumour model used. The timing of administration may be less important than
previously thought.
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One of the main problems in the treatment of cancer is to
define therapeutic approaches specifically directed against
tumour cells, and which are non-toxic for normal cells.
Rodent and xenografted human tumours contain hypoxic
cells which are radioresistant (Rockwell and Moulder 1990;
Guichard, 1989) and/or resistant to some cytotoxic drugs,
such as alkylating agents (Teicher et al., 1981; Sakata et al.,
1991). In patients, tumour tissues are less well oxygenated
than normal tissues (Vaupel, 1990; Lartigau et al., 1993;
1994) and hypoxic tumour cells could be a specific target for
various treatment modalities (Coleman, 1988).
There have been efforts over the last 30 years to overcome
radioresistance due to cellular hypoxia (Overgaard, 1991).
Concerning the chemoresistance due to hypoxia, most of the
studies have looked at the variations in efficacy of drugs
when exposed to air or severe hypoxia (Teicher et al., 1981).
More recently, studies have focused on the cytotoxicity of
drugs at various oxygen tensions (Po2). Of particular interest
are the bioreductive drugs, which are activated under hypoxic
conditions to form cytotoxic metabolites (Workman and
Stratford, 1993). To be active against tumour cells and non-
toxic to normal cells, these drugs must be metabolised at the
low Po2 levels most often present in the tumours, i.e. around
0.2% of oxygen or 1.5 mmHg (Vaupel, 1990; Lartigau et al.,
1993).
The bioreductive drug tirapazamine (SR4233, WIN
59075) has been investigated in vitro and in vivo for its
cytotoxic and/or radiosensitising activity against tumour cells
in air and in hypoxia (Zeman et al., 1986, 1988, 1990; Brown,
1993; Koch, 1993). A higher aerobic-hypoxic ratio
(concentration in air -concentration in nitrogen to obtain
the same cytotoxicity) have been found in murine than in
human tumours (Zeman et al., 1986). More recent data on
murine tumours have shown that the cytotoxicity of
tirapazamine in vitro and in vivo is significantly increased
when combined with other chemotherapy drugs such as
cisplatinum, a frequently used drug in the treatment of
malignancies (mainly embryonal tumours and squamous
carcinoma) (Holden et al., 1992; Dorie and Brown, 1993).
With this last drug, highly significant cell toxicity was
demonstrated in a murine tumour, RIF-1, together with
dose and time dependence. The maximal response was
observed when tirapazamine was given 2-3 h before c-
DDP (Dorie and Brown, 1993). Furthermore, tirapazamine
did not enhance the kidney damages resulting from c-DDP
(Dorie and Brown, 1993).
Other drugs are routinely used in clinical practice, such as
5-fluorouracil (5-FU), bleomycin (bleo), etoposide (VP16)
and dacarbazine (DTIC). These drugs are given alone or in
combination and according to tumour type. Thus for
example, DTIC is the reference chemotherapy agent in
advanced melanoma. Furthermore, the activity of these
drugs varies according to Po2. Bleo and DTIC are
preferentially toxic to aerobic cells and 5-FU and c-DDP
have no selective toxicity based on cellular oxygenation
(Teicher et al., 1981). To our knowledge no data are available
for VP16. To increase tumour cell toxicity, it could be useful
to combine drugs activated under hypoxia and drugs toxic
against aerobic cells or without any oxygen-dependent
activity.
We decided to test the in vivo effects of tirapazamine alone
and combined with other chemotherapy agents on two
human cell lines: a rectal adenocarcinoma (HRT18) and a
melanoma (Nal 1+). The choice of the chemotherapy agents
was based on their known activity in human models.
Different assays were used (animal lethality, growth delay
assay, excision assay) for tirapazamine given alone or
combined with the various agents (5-FU, VP16, bleo, DTIC
and c-DDP) on nude mice bearing the two xenografted
human tumours.
Materials and methods
Drugs
All the drugs were injected intraperitoneally (i.p.). Tirapaza-
mine (3-amino-1,2,4-benzotriazinel,4-dioxide, SR-4233, WIN
59075, supplied by Sterling Drug), c-DDP (Roger Bellon) and
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VP16 (Sandoz) were dissolved in normal saline, whereas 5-
FU (Roche), bleo and DTIC (Roger Bellon) were dissolved in
sterile water. To mimic common clinical practice, the drugs
were injected alone or in combination for four successive
days, except c-DDP, which was injected only once. The total
volume injected per drug was 0.1-0.3 ml depending on the
concentration used, for a total daily injected volume per
animal of 0.2-0.6 ml if two drugs were combined. In
combination, tirapazamine was injected immediately before
or 3 h before the other drug.
Cell lines and anunals
Two human tumour cells lines were used: a melanoma (Na
11 +) and a rectal adenocarcinoma (HRT 18). The
characteristics and the maintenance of the cell lines have
already been published (Guichard et al., 1977, 1983). The
percentage of radiobiologically hypoxic cells is around 15%
for HRT18 and 60% for NAl 1+. A cell suspension (3 x 106
cells in 0.5 ml of medium) was inoculated into each flank of
the animals (two tumours per animal). The animal
experiments were performed under the control of Dr M
Guichard (animal care licence no. 0167 from the Ministere
Francais de l'Agriculture et de la Foret) and according to the
UKCCCR (1988).
Lethality
Different dosages of drugs (alone or combined) were injected
for 4 days to estimate approximately the doses giving 10%
lethality (LD,o). The rationale behind this is that a linear
relationship exists between the LD,o doses ofcyctotoxic drugs
in mice and their maximum tolerated doses in man (Steel and
Peckham 1992). All surviving animals were sacrificed at 3
months.
Growth delay assay
This assay was performed for animals treated by tirapaza-
mine, bleo, 5-FU, VP16 and DTIC given alone or combined.
The tumours were measured two or three times a week (three
orthogonal diameters) using a vernier caliper. Tumour
volumes were calculated using the formula of a hemiellip-
soid, the geometric figure most nearly approximating the
shape of the tumours. At the time of treatment, the tumour
volumes ranged from 75 to 225 mm3. The growth delay assay
was determined by measuring the time taken for the tumour
to double in volume from the first day ofdrug injections. The
specific growth delay was calculated according to the Steel
and Peckham (1992) formula:
Specific growth delay = T2 T,
T,
where T, is the time taken in days for control tumours and T2
the time for treated tumours to double in volume. Specific
growth delay can be regarded as an estimate of the number
of volume doubling times by which growth is delayed and
permits comparisons of therapeutic response between
tumours of different growth rates.
Excision assay
The efficacy of the drug giving the longest growth delay in
combination with tirazapamine (4 day schedule) was tested
with an in vivo-in vitro colony assay, i.e. bleo for HRT18
and VP16 for Nal1 +. The mice were killed 24 h after the
last drug injection and the tumours were excised, minced and
dissociated with an enzyme cocktail. The cell suspension was
filtered and the cells plated for clonogenic assay. After 2
weeks of incubation (37°C, 5% carbon dioxide humidified
atmosphere), the colonies were fixed, stained with a solution
of crystal violet and counted.
c-DDP efficacy was tested with an excision assay following
a protocol based on previously published studies (single day
injection) (Dorie and Brown 1993). The effect of the different
treatments on the relative clonogenicity was calculated as the
product ofplating efficiency and tumour cell yield for treated
tumours relative to that for control untreated tumours
assayed i\n parallel. Three to four experiments were
performed with five mice per group and the results were
averaged. The cell yield and plating efficiency were compared
using a non-parametric Mann-Whitney test.
Resuls
Lethality(Table I)
After a single drug injection, the LD 10 was reached for a
total injected dose of 80 mg kg-' for VP16 and 144 mg kg-l
for tirapazamine. For 5-FU, there was no lethality for a total
injected dose of 120 mg kg-', but it was 45% for a dose of
160 mg kg-' of body weight. For bleo and DTIC, the 10%
lethality dose was not reached with doses injected above the
tolerable dose in patients.
When the drugs were combined, there was often a marked
increase in toxicity (Table II). To perform the experiments at
the LD,o level and to be able to keep tirapazamine at the
total injected dose of 144 mg kg-', it was necessary to
decrease the total dose ofall injected drugs (for example from
120 mg kg-' to 40 mg kg-' for 5-FU). When tirapazamine
was injected 3 h before VP16, 5-FU or bleo instead of
immediately, a significant increase in lethality was noted only
with bleo (17% lethality with simultaneous injections vs 50%
lethality with a 3 h interval). Most of the animals had
terminal cachexia and were culled before the occurrence of
predictable death. For the combination of tirapazamine and
5-FU, diarrhoea was recorded in half of the animals. This
toxicity was present for the high doses of 5-FU (30 and
40 mg kg-'), together with skin toxicity. For this dosage of
5-FU, a brisk erythema has always preceded the death of the
animals. As far as an estimated 10% lethality was concerned,
the times of death were not significantly different when
tirapazamine given alone was compared with tirapazamine
combined with another drug.
Tumour doubling time and specific growth delas' (Table III)
HRT18 Treatment with tirazapamine, VP16 or 5-FU alone
did not delay tumour regrowth. Only bleo alone significantly
delayed tumour regrowth (P=0.001). Tumour growth was
constant for HRT18. The combination of tirapazamine and
bleomycin significantly increased the delay of regrowth
compared with that produced by bleomycin or tirapazamine
alone (P=0.04) (Figure 1). The regrowth delay produced
Table I Animal lethalty after four dailyinjections of a single drug
Nwnber Mean time of
Dad)l dosage ( x4) Lethaitiy of death (days)
(mgkg1l) (mgm 2) (%) animals (±s.e.j
5-FU 30 102 0 18 -
40 136 45 11 53(± 7)
50 170 40 20 39 (5)
VP16 15 51 10 20 34 ( 9)
20 68 13 24 23 (5)
25 85 36 11 23(±3)
Bleo 10 34 0 18 -
15 51 0 13 -
25 85 6 18 23(± 1)
Tirapazanune 27 92 0 10 -
36 122 12 26 45 (± 3)
45 153 30 7 41(±2)
DTIC 100 340 0 5 -
125 425 0 13 -dof UV -7- an xeimtsd Imnu bunou
rt E Lrtigau Mad M Guichad
1482
Table I Animal lethality after 4 day injections of combined drugs
Lethality Number Mean time ofdeath
(%) ofaninals (+s.e.)
Tirapazamine immediately before
Tirapazanine (27)a + VP16 (20)a 10 10 25 (± 4)
Tirapazamine (36) + VP16 (20) 33 24 20 (± 11)
Tirapazanine (27) + 5-FU (40) 100 10 10 (± 1)
Tirapazaiine (36) + 5-FU (10) 25 12 31 (± 15)
Tirapazamine (36) + 5-FU (30) 100 8 39 10)
Tirapazamine (27) + bleo (15) 0 11
Tirapazamine (36) + bleo (15) 17 12 44 (_ 5)
Tirapazamine (36) + bleo (25) 25 8 36 (± 2)
Tirapazamine (45) + bleo (25) 38 8 10 (± 2)
Tirapazamine (36) + DTIC (100) 13 16 41 (± 20)
Tirapazamine 3 h before
Tirapazamine (36) + VP16 (20) 33 10 21 (± 5)
Tirapazamine(36) + 5-FU (10) 33 10 45 ( 6)
Tirapazanine (36) + bleo (15) 50 8 58 (± 10)
a Figures in brackets represent daily dose in mg kg . Statistically significant difference compared
with control
Table III Tumour doubling time and specific growth delay (SGD) after 4 day injections with single
drug or combined injections
Doubling time
(mean, 95% CI )
SGD
(s.d.)
HRT18
Control (saline)
Tirapazanine (36)a
VP16 (20)
5-FU (30)
Bleo (25)
Simultaneous injections
Tirapazamine (36) + VP16 (20)
Tirapazanine (36) + 5-FU (10)
Tirapazamine (36) +Bleo (15)
Tirapazamine 3 h before
Tirapazamine (36) + VP16 (20)
Tirapazamine (36) + 5-FU (10)
Tirapazamine (36) + Bleo (15)
Na 11+
Control (saline)
Tirapazamine (36)
VP16 (20)
5-FU (30)
Bleo (25)
DTIC (125)
Simultaneous injections
Tirapazamine (36) + VP16 (20)
Tirapazamine (36) + 5-FU (10)
Tirapazamine (36) + Bleo (15)
Tirapzazmine (36) + DTIC (125)
Tirapazamine 3 h before
Tirapazanine (36) + VP16 (20)
17.9 (7.3-28.4)
14.3 (10.0-18.6)
18.6 (15.3-21.8)
14.3 (11.0- 17.5)
36.5' (19.3-53.6)
20.3 (15.8-24.8)
20.4 (12.4-28.2)
76.9- (20.0-133.8)
21.1 (18.4-23.7)
19.9 (16.3-23.4)
41.8* (25.4-58.0)
14.6 (9.9-19.2)
12.9 (11.7- 14.2)
17.4 (13.4-25.5)
12.7 (8.7- 16.8)
18.9 (15.6-22.2)
21.7- (17.8-25.7)
22.4- (10.0-34.8)
15.7 (12.0-19.4)
21.9- (17.0-26.7)
23.5* (18.5-28.5)
0
0
0
0
1.0 (+ 0.6)
0.1 (+1 0.2)
0.1 (+ 0.1)
3.3 (+ 1.6)
0.2 (+ 0.3)
0.1 (+ 0.3)
1.3 (± 0.2)
0
0
0.3 (+
0
0.4 (+
0.5 (+
0.5 (+
0
0.5 (+
0.6 (+
0.7)
0.8)
0.9)
0.7)
1.1)
0.8)
21.7' (16.3-27.1 ) 0.5 (+ 0.8)
aFiguresinbrackets represent daily dose in mgkg-1.Statistically significant differencecomparedwith
control.
when tirapazamine was administered 3 h before bleomycin
was not significantly different from that produced when
tirapazamine and bleomycin were administered simulta-
neously. The longest specific growth delay was observed
with the combination of tirapazamine and bleo (SGD = 3.3).
NAII+ Treatment with bleo or DTIC alone significantly
increased the tumour doubling time compared with the
controls (P=0.02), which was not the case for VP16
(P=0.14). The combination of tirapazamine with bleo or
DTIC significantly increased the tumour doubling time
(P=0.001), but this increase was not significant compared
with bleo or DTIC administered alone. If one considers the
initial part of the growth curve (the first 30 days), the
combination of tirapazamine with VP16 significantly
increased tumour doubling time compared with the controls
(P=0.001) or VP16 alone. However, it has to be emphasised
that tumour growth was not constant after treatment for
some of the animals. In experiments with bleo, tirapazamine
or VP16 alone, or with combined tirapazamine and bleo or
combined tirapazamine and VP16, a marked decrease in
tumour growth was noted at day 30 (Figure 2). The effect
was present in one-third of the animals and in these cases the
calculated volume doubling time did not reflect precisely
tumour growth. The specific growth delay observed with the
combination of tirapazamine and VP16 was only 0.5.EffUc of tboiazuum mu xeo ted hI bznours
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Excision assay (Tables IV and V)
For HRT18, the cell yield was significantly decreased with
the combination of tirapazamine and bleo compared with
the control group (P=0.015) (Table IV). However, an
increase in cell yield was observed when tirapazamine was
injected 3 h before bleo compared with simultaneous
injection. The plating efficiency was significantly decreased
with bleo alone (P=0.001), tirapazamine and bleo
(P=0.0001) and tirapazamine 3h before bleo (P=0.001)
compared with the control group. The combination of
tirapazamine and bleomycine was more cytotoxic than
tirapazamine alone (P=0.04), but not different from
bleomycine alone (P=0.06). There was no difference
between tirapazamine given 3 h or immediately before
bleomycin. The lowest relative clonogenicity was observed
with the combination of tirapazamine and bleo given at the
same time (0.12). The effect of the combination of
tirapazamine and c-DDP was comparable with tirapaza-
mine alone, and did not differ from the control group.
For the Nall+ cell line, there was no significant
modification of the cell yield with VP16 and tirapazamine
E
E
0
E
6
0
0
alone or combined (Table IV). A significant decrease in plating
efficiency was observed with tirapazamine alone (P=0.002),
and tirapmine and VP16 (P=0.0001). Tirapazanine was
more effective than VP16 (P=0.005), and the combination of
tirapazamine and VP16 was more effective than VP16 alone
(P=0.0001). There was no difference between tirapazaiine
given 3 h or immediately before VP16. The lowest relative
clonogenicity was observed with the combination of
tirapazamine and VP16 given at the same time (0.21). With
c-DDP, no differences were detected for the cell yield in
treated animals with the controls (Table V). There was a
significant decrease in plating efficiency when tirapazamine
and c-DDP were given at the same time (P=0.04), compared
with c-DDP or tirapazamine alone. This effect was not
significant with a 3 h interval between the injections.
Diacssion
In patients, polarographic studies have shown large
differences in oxygenation between normal tissues and
tumours (Vaupel, 1990; Lartigau et al., 1993). In tumours
E
E E
0
E
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Figue 1 Tumour growth for xenografted rectal carcinoma
(HRT18) after control (A-A), tirapazamine (M--), bleo (-
- -)
or tirapazamine and bleo (fl-O) injections. Pooled values for
three different experiments (mean values and 95% confidence
intervals are shown).
0 20 40 60 80
Days
Figue 2 Tumour growth for xenografted melanoma (Nal 1+)
after tirapazamine and VP16 injections. Five individual tumours
are presented.
Table IV Cell yield and plating efficiency after four daily injections oftirapazamine, bleo and VP16
Relative
Cell yield Plating efficien clonogenicity
(mean x 106, 95% CI) (mean, 95% CI) (s.d.)
HRT18
Control (saline) 3.13 0.51
(1.38-4.88) (0.39-0.62)
Tirapazamine (36)a 2.41 0.35 0.53 (+0.28)
(1.32-3.50) (0.20-0.49)
Bleo (25) 1.76 0.17* 0.18 (+0.14)
(0.84-2.68) (0.13-0.20)
Tirap (36) + bleo (15) 1.61* 0.12* 0.12 (+0.21)
(0.17-3.40) (0.04-0.19)
Tirapa (36)- 3h-bleo (15) 4.12 0.09* 0.24 (+0.11)
(1.88-6.36) (0.04-0.14)
Na 11+
Control (saline) 0.38 0.20
(0.17-0.60) (0.14-0.26)
Tirapazamine (36) 0.30 0.09 0.35 (±0.37)
(0.21-0.38) (0.06-0.12)
VP16 (20) 0.31 0.18 0.73 (+0.40)
(0.21-0.40) (0.13-0.23)
Tirapazamine (36) + VP16 (20) 0.33 0.05 0.21 (+0.18)
(0.22-0.43) (0.03-0.07) Tirapazainn (36)- 3h-VP16 (20) 0.22 0.09 0.26 (+0.18)
(0.12-0.32) (0.05-0.12)
aFigures in brackets represent daily dose in mg kg-'. Statistically significant difference compared
with control.
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Table V Mean cell yield and plating efficiency after one day injection of tirapazamine and cisplatinum for Nal +
Cell yield Plating efficiency Relative clonogenicity
(mean x 106, 95% CI) (mean, 95% CI) (s.d.)
Control (saline) 0.72 0.16
(0.2-1.46) (0.05-0.49)
Tirapazamine (36)a 0.79 0.10 0.71 (±0.37)
(0.2- 1.6) (0.03-0.38)
c-DDP (8) 0.42 0.05 0.19 (±0.50)
(0.3-0.55) (0.02-0.11)
Tirapazamine (36) +c-DDP (8) 1.15 0.01 0.10 (+0.21)
(0.6-2.24) (0.003-0.03)
Tirapazamine (36)-3h-c-DDP (8) 0.37 0.03 0.10 (+0.33)
(0.2-0.54) (0.01 -0.11)
aFigures in brackets represent daily dose in mg kg- 1 Statistically significantdifference compared with control.
Po2 variations have been found from values superior to
20 mmHg, down to very low values (below 2 mmHg), with
large variations between tumours (Gatenby et al., 1988;
Vaupel, 1990; Lartigau et al., 1993; H6ckel et al., 1993). Very
low Po, values can represent more than 25% of the recorded
values in metastatic neck nodes (Lartigau et al., 1993), but
are very uncommon in normal tissues (Vaupel, 1990; Lartigau
et al., 1993, 1994). Thus, tumour hypoxia could represent a
target for anti-cancer therapies, with the aim of being more
specifically cytotoxic against hypoxic clonogenic tumour cells.
Some anti-cancer agents, so-called 'bioreductive drugs', are
activated in toxic metabolites only in the case of low Po2.
Their cytotoxicity in patients will depend on the drug
concentration in the tumour, on the drug reduction as a
function of the enzyme concentration and on the oxygen
tension in the tumour (Bremmer, 1990; Koch, 1993; Brown,
1993; Workman and Stratford, 1993). One of the bioreduc-
tive drugs currently being tested in phase I in man (Doherty
et al., 1994) is tirapazamine (SR-4233). Tirapazamine has a
lower hypoxic cytotoxic ratio in human cell lines (between 15
and 50) than in murine cell lines (Zeman et al., 1986), and it
has recently been shown that tirapazam ne toxicity extends
over a large range of oxygen concentrations (Costa et al.,
1989; Koch, 1993; Lartigau and Guichard, 1995).
To improve tumour control, the combination of radio-
therapy and chemotherapy is currently strongly advocated
(Schilsky, 1992; Rockwell, 1992). The bioreductive drugs
could be associated to agents more cytotoxic in air than in
hypoxia (bleo, procarbazine, vincristine), or to agents without
any selective cytotoxicity according to tissue oxygenation (5-
FU, c-DDP) (Teicher et al., 1981). Before clinical implemen-
tation, such combinations have first to be tested in relevant
experimental models.
Concerning mouse lethality, a 10% lethality with
tirapazamine alone was obtained for a total injected dose
of around 500 mg m-2, corresponding to four successive daily
injections of 0.20 mmol kg-' or 36 mg kg-'. These results
are similar to those obtained by others with rodent tumours
(Zeman et al., 1986; Minchinton et al., 1992; Spiegel et al.,
1993). However, it must be emphasised that, in this study, the
combination of tirapazamine and other chemotherapy agent
always increased mice lethality. It was necessary to decrease
the LD 10% for all the drugs in order to retain the LD 10%
dose of tirapmine. This was particularly true for 5-FU
which produced high gastrointestinal toxicity (diarrhoea) with
animal cachexia.
Concerning tumour growth delay, a marked effect was
noted only with the combination of tirapaine and bleo
for the rectal adenocarcinoma, even with different injection
times. This shows that two parameters are crucial: the drugs
used and the tumour assessed. In our experiments, only the
combination of a drug active against hypoxic cells
(tirapazamine) and a drug active against aerobic cells
(bleo) was efficient in a tumour model with a relatively
low percentage of hypoxic cells (15-20%). Tirapazamine
seems to have enhanced the activity of a drug (bleo) that
was already very active on most of the cells present in the
tumour. For the other drugs, in the two different tumour
cell lines, the effect was not so pronounced. These results are
similar to results obtained by other groups, which have
consistently shown a limited effect of tirapazamine alone in
tumour growth delay assays with murine or human cell lines
(Minchinton et al., 1992; SF Chen, personal communica-
tion). For a human colon cell line (HT29), tirapazamine or
c-DDP had only marginal anti-tumour effect in an in vivo
tumour growth delay assay (SF Chen, personal communica-
tion). For Nail +, a modification in tumour growth was
noticed with delayed cytotoxicity. However, for this cell line
the calculated volume doubling time and specific growth
delay did not reflect precisely the biological effect of the
drugs. The biological effect was in fact larger than that
appreciated only with the calculation of the tumour
doubling time. The late decrease in tumour volume, noticed
at day 30 only, may have depended on the time necessary
for this anoxic tumour to eliminate the dead cells.
For the excision assay, some effects on plating efficiency
were noticed with the combination of drugs found to be the
most active in the growth delay assay: tirapazamme and bleo
for HRT18 and tirapazamine and VP16 for Nall +.
However, the effect of these drugs were not as marked as
those previously published by Holden or Dorie, who showed
a very marked increase in toxicity when tirapazamine was
injected 3 h before c-DDP (Holden et al., 1992; Dorie and
Brown, 1993). In particular, the timing of administration was
not crucial in our experiments and the administration of
tirapazamine 3 h before the other drug did not increase
significantly tumour cell kill. We have no explanation for
these differences. However, it must be emphasised that
variations in experimental results can be found when using
different tumour models, as for example between human and
murine cell lines (Guichard, 1989). For the combination of
tirapazamine and c-DDP a marked increase in plating
efficiency was noted for HRT18, with the opposite effect
for Na 11+. We have no explanation for such a result, but
we feel that it should lead to more caution about using such a
combination in patients.
In conclusion, tirapazamine was shown to be cytotoxic in
vivo against clonogenic tumour cells. This efficacy may
depend on the combination of tirapazamine with already
active chemotherapy drugs on the tumour model studied
(bleo on HRT18 and VP16 on Nal1 +). Some late effect on
tumour growth was found in one of our xenografted tumours
(Nal 1+), this not being precisely demonstrated by the
calculation of the volume doubling time. Thus, the model
used is very important to describe precisely the biological
effect observed. Finally, the timing of drug administration
and combination could be less important than previously
thought (Dorie and Brown, 1993).of ct f a on x ftd huu uows
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